EMA Recommends Extension of Indications for Acalabrutinib to Include the Treatment for Patients with MCL By Ogkologos - April 3, 2025 763 0 Facebook Twitter Google+ Pinterest WhatsApp New indication concerns the treatment of patients with relapsed or refractory mantle cell lymphoma Source RELATED ARTICLESMORE FROM AUTHOR FX-909 Demonstrates Acceptable Safety and Preliminary Antitumour Activity, Establishing a Proof of Concept for PPARγ Inverse Agonism in Advanced Urothelial Cancer Pimicotinib Shows Robust Antitumour Activity and Clinically Meaningful Improvements in Patients with Tenosynovial Giant Cell Tumour FDA Grants Accelerated Approval to Zongertinib for Unresectable or Metastatic Non-Squamous NSCLC MOST POPULAR Coming together for Zynlonta July 2, 2021 Despite Proven Safety of HPV Vaccines, More Parents Have Concerns October 22, 2021 2021/22 in review: Charity looks to the future with ambitious new... July 21, 2022 Evaluating Targeted Therapy for People With Advanced Gastric or Gastroesophageal Junction... March 21, 2023 Load more HOT NEWS Veteran Dresses As Captain America & Brings Joy To Children In... Does Sugar Feed Cancer? Working to Raise Prostate Cancer Awareness: A Patient Advocate’s Story Biomarkers of Pro-Inflammatory Response May Identifiy Cancer Patients at Risk of...
